GlassScriptPhysician profile
Susan Bohnenkamp
$3,785.69
in general payments reported to CMS, 2019-2025
17 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $616 · 2023: $454 · 2024: $961 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.46 |
| Education | $386.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,022.32 | 2022-2025 | Rybrevant, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $349.01 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $332.76 | 2024-2025 | Reblozyl, Opdivo |
| Jazz Pharmaceuticals INC. | $324.36 | 2025 | |
| Glaxosmithkline, LLC. | $246.30 | 2024-2025 | Jemperli, Ojjaara |
| Medtronic, INC. | $221.43 | 2022-2025 | Synchromedii |
| Astellas Pharma US INC | $188.92 | 2022-2023 | Padcev |
| Boston Scientific Corporation | $133.23 | 2023 | Watchman Access System |
| Emd Serono, INC. | $125.00 | 2025 | |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart |
| Genmab U.S., INC. | $124.26 | 2025 | Tivdak |
| Stemline Therapeutics INC. | $121.83 | 2023 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $121.83 | 2025 | Fruzaqla |
| Seagen INC. | $121.83 | 2022 | |
| Servier Pharmaceuticals LLC | $110.42 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $86.19 | 2022 | |
| Syndax Pharmaceuticals, INC. | $31.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bohnenkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.